0000000000718463

AUTHOR

Jeremy Barben

showing 1 related works from this author

Correction to: The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome

2021

Although immune modulation is a promising therapeutic avenue in coronavirus disease 2019 (COVID-19), the most relevant targets remain to be found. COVID-19 has peculiar characteristics and outcomes, suggesting a unique immunopathogenesis.Thirty-six immunocompetent non-COVID-19 and 27 COVID-19 patients with severe pneumonia were prospectively enrolled in a single center, most requiring intensive care. Clinical and biological characteristics (including T cell phenotype and function and plasma concentrations of 30 cytokines) and outcomes were compared.At similar baseline respiratory severity, COVID-19 patients required mechanical ventilation for significantly longer than non-COVID-19 patients …

Male2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Critical CareSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralMEDLINElcsh:MedicineLymphocyte ActivationSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular BiologyImmunophenotypingmedicineHumansAgedAged 80 and overInnate immune systembusiness.industrySARS-CoV-2lcsh:RCorrectionCOVID-19General MedicineMiddle Agedmedicine.diseasePrognosisRespiration ArtificialImmunity InnatePneumoniaImmunologyFemaleFrancebusinessJournal of Translational Medicine
researchProduct